Study Links Fetal Fibronectin Testing With Changes In Management Decisions For Symptomatic And Asymptomatic Women At Risk For Preterm Birth

Hologic, Inc. (Nasdaq: HOLX), a leading developer, manufacturer and supplier of premium diagnostics, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, announced the publication of the first of its kind study evaluating the impact of fetal fibronectin (fFN) testing among both symptomatic and asymptomatic pregnant women at risk for preterm birth.